Versant Venture Management LLC's Q3 2026 13F: 1 new position, 1 exit

Form 13F-HR for the quarter ended Sep 30, 2026 · filed Nov 13, 2026 · 8 reported positions · accession 0001193125-26-460919

What changed this quarter

Versant Venture Management LLC's changes in reported equity positions, Q3 2026
Activity Security Weight before Weight now Change Shares Shares %
Increased Contineum Therapeutics, Inc. (CTNM) 5.5% 15.9% +10.4 pts +750K sh +138%
Exited Skye Bioscience, Inc. (SKYE) 0.9% — −0.9 pts −2.01M sh −100%
New Skye Bioscience, Inc. (SKYEZZZZ) — 0.4% +0.4 pts +251K sh new

Reported by the fund in its Form 13F filed with the SEC; holdings are as of the quarter-end report date and may have changed since. For informational purposes only — not investment advice or a recommendation to buy or sell any security. FilingExplorer is not affiliated with or endorsed by this fund. How this brief is compiled

Top 10 positions — 100.0% of the equity book

Changes in the top 10 this quarter: SKYEZZZZ entered · SKYE left

# Security Weight before Weight now
1 Monte Rosa Therapeutics, Inc. (GLUE) 47.3% 34.8%
2 Century Therapeutics, Inc. (IPSC) 18.3% 19.1%
3 Contineum Therapeutics, Inc. (CTNM) 5.5% 15.9%
4 Jade Biosciences, Inc. (JBIO) 13.6% 12.8%
5 Lenz Therapeutics, Inc. (LENZ) 9.3% 9.4%
6 CRISPR Therapeutics AG (CRSP) 5.0% 7.5%
7 Skye Bioscience, Inc. (SKYEZZZZ) 0.0% 0.4% Entered the top 10
8 Tempest Therapeutics, Inc. (TPST) 0.2% 0.2%
— Skye Bioscience, Inc. (SKYE) 0.9% 0.0% Left the top 10

Weights are each position's reported value as a share of the fund's reported equity positions (options and principal-amount holdings excluded).